Atom Investors’s AtriCure ATRC Stock Holding History

Atom Investors’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-26,500	Closed	-$661K	–	239
2019 Q3	$661K	Buy	+26,500	New	+$757K	0.05%	205

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Atom Investors's ATRC Position: Q4 2024 in Review

Atom Investors sold out of AtriCure (ATRC) in Q4 2024, closing a stake of 62,095 shares — an estimated $1.74M sold.

Atom Investors first reported a position in ATRC in Q4 2018 and held it in 2 quarters. The position peaked at $1.74M in Q3 2024. 213 funds tracked by Wall St. Rank hold ATRC as of Q4 2024.

Atom Investors reported no remaining AtriCure position as of Q4 2024 after selling out during the quarter.
Atom Investors sold 62,095 AtriCure shares in Q4 2024, an estimated $1.74M.
Atom Investors first reported a position in AtriCure in Q4 2018 and held it in 2 quarters.
Atom Investors's AtriCure position peaked at $1.74M in Q3 2024.
213 funds tracked by Wall St. Rank held AtriCure as of Q4 2024.

Based on Atom Investors's 13F filing for Q4 2024, filed 14 Feb 2025.